After intracranial inoculation with luciferase-labeled CTL-U251 or TR-U251 cells, mice were randomized into 4 groups. Bioluminescent images were recorded using an IVIS Lumina II Bioluminescence System (PerkinElmer) every 7 days. Total photon flux values were quantified in tumor progression between treatment groups, as described in Sachdeva et al. 2019 (15). (A) Schematic showing in vivo experimental design for cells injected intracranially and thereafter treated with lomitapide, TMZ, or concomitant lomitapide and TMZ. (B) Bioluminescence imaging of intracranial glioblastoma mouse xenograft visualizing tumor growth of CTL-U251 cells. Empty spaces indicate sacrificed mice at humane endpoints. (C) Signal progression of total flux activity comparing tumor growth at 1- to 4-weeks after inoculation. (D) Total photon flux of concomitant TMZ and lomitapide-treated and TMZ alone–treated mice 1–4 weeks following transplantation. 2-tailed Student’s t test was used for statistical comparison between 2 groups. (E) Kaplan–Meier survival curves of mice injected with CTL-U251 in individual cohorts (n = 16). *P = 0.0239 for lomitapide + TMZ versus TMZ; **P = 0.0015 for lomitapide + TMZ versus lomitapide; **P = 0.013 for lomitapide + TMZ versus Control. (F) Kaplan–Meier survival curves of mice injected with TR-U251 in individual cohorts (n = 12). Median survival and statistical significance were determined by log-rank test corrected for multiple comparisons: ****P < 0.0001 for lomitapide + TMZ vs TMZ; P < 0.0001 for lomitapide + TMZ vs Control.